Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

Rhea-AI Summary

Revolution Medicines (Nasdaq: RVMD) will host an investor webcast to update on its RMC-6236 pancreatic ductal adenocarcinoma (PDAC) clinical development program. The webcast is scheduled for July 15, 2024, at 8:00 a.m. Eastern Time. Speakers include the company's management and Dr. Brian M. Wolpin from Harvard Medical School and Dana-Farber Cancer Institute. The event can be accessed via the company's 'Events & Presentations' page. A replay will be available for 14 days post-event.

Positive

• Scheduled investor webcast to potentially boost investor confidence.
• Involvement of renowned experts like Dr. Brian M. Wolpin may add credibility.

Negative

• No new clinical data or results disclosed in the announcement.

REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide an update on its RMC-6236 pancreatic ductal adenocarcinoma (PDAC) clinical development program. Speakers will include members of Revolution Medicines’ management team, along with Brian M. Wolpin, M.D., M.P.H., professor of medicine at Harvard Medical School, and director of the Gastrointestinal Cancer Center and Robert T. & Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute.

The webcast will take place at 8:00 a.m. Eastern Time on Monday, July 15, 2024. To access the live webcast, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the event.

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities include its RAS(ON) mutant-selective inhibitors RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

FAQ

When will Revolution Medicines provide an update on the RMC-6236 PDAC program?

Revolution Medicines will provide an update on the RMC-6236 PDAC program on July 15, 2024, at 8:00 a.m. Eastern Time during an investor webcast.

How can I access the Revolution Medicines RMC-6236 PDAC program update webcast?

The webcast can be accessed on Revolution Medicines' 'Events & Presentations' page on their website.

Will a replay of the RMC-6236 PDAC program update webcast be available?

Yes, a replay of the webcast will be available on the 'Events & Presentations' page of Revolution Medicines' website for at least 14 days following the event.

Who are the speakers for the Revolution Medicines RMC-6236 PDAC update webcast?

Speakers include members of Revolution Medicines' management team and Dr. Brian M. Wolpin from Harvard Medical School and Dana-Farber Cancer Institute.

What is the stock symbol for Revolution Medicines?

The stock symbol for Revolution Medicines is RVMD.